Mitoxantrone: an active, new antitumor agent with an improved therapeutic index-Reference-Cited by-同舟云学术

Mitoxantrone: an active, new antitumor agent with an improved therapeutic index

Published:1987-12 Issue:3-4 Volume:14 Page:297-303
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Saletan S.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference13 articles.

1. Daunomycin (NSC-82151) and adriamycin (NSC-123127);Adamson,1974

2. Mechanism of action and pharmacokinctics of Novantrone in intravenous and intraperitoneal therapy;Alberts,1985

3. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and 5-fluorouracil (CNF) to doxorubicin, cyclophosphamide, and 5-fluorouracil (CAF) in the therapy of metastatic breast carcinoma;Bennett;J. Clin. Oncol.,1987

4. Randomized trial of Novantrone, bisantrene, and Adriamycin in advanced breast cancer;Cowan,1986

5. Cardiac events in patients receiving mitoxantrone;Dukart,1984

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anthracyclines and trastuzumab associated cardiotoxicity: is the gut microbiota a friend or foe? – a mini-review;Frontiers in Microbiomes;2023-09-08

2. Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection;Frontiers in Cardiovascular Medicine;2022-04-15

3. Identification of the key target profiles underlying the drugs of narrow therapeutic index for treating cancer and cardiovascular disease;Computational and Structural Biotechnology Journal;2021

4. Cardiovascular Toxicities of Chemotherapy;Handbook of Cancer Treatment-Related Symptons and Toxicities;2020

5. Assessment of anthracycline-induced long-term cardiotoxicity in patients with hematological malignancies;Iraqi Journal of Hematology;2019